Akeso Inc. shares plunged as much as 19% in Hong Kong on Monday morning after preliminary data for its new cancer drug fell ...

Akeso has shared for the first time overall survival data from a high-profile Keytruda head-to-head trial for its PD-1xVEGF ...

Following a positive readout for its closely watched PD-1xVEGF bispecific ivonescimab, Akeso has won the FDA’s go-ahead for ...

Akeso, a Chinese biotech that made headlines for beating Merck’s Keytruda in a head-to-head trial, won approval in China this ...

Akeso Pharmaceuticals and Summit Therapeutics have reported that their PD-1/VEGF bispecific antibody has met the primary endpoint in a Phase III trial in patients with squamous non-small cell lung ...

Interim results from a study in China suggest ivonescimab may reduce the risk of death versus Keytruda, but the difference ...

The US Food and Drug Administration (FDA) has granted approval to Akeso's differentiated programmed cell death protein 1 ...

Approval of penpulimab-kcqx marks the company’s US regulatory debut and introduces a new immunotherapy option for advanced ...

Penpulimab has picked up a pair of approvals in nasopharyngeal carcinoma (NPC), becoming only the second drug to be cleared ...

Chinese regulator grants second approval for lung cancer drug ivonescimab, which has outperformed Merck’s Keytruda in phase ...

Keytruda is set to lose exclusivity in 2028, meaning Summit may face competition from cheaper biosimilars. Meanwhile, other ...

With ivonescimab’s data coming solely from China, its prospects in the U.S., where Summit owns the rights, remain up in the ...